Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Chronic myelomonocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Chronic myelomonocytic leukaemia

Recruiting

Registered drugNo placebo

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:TAGRAXOFUSP

Contact Research Centre

Chronic myelomonocytic leukaemia+3

Recruiting

InvestigationalNo placebo

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cedazuridine

Contact Research Centre

Chronic myelomonocytic leukaemia+2

Not yet recruiting

Registered drugNo placebo

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Posaconazole

Contact Research Centre

Chronic myelomonocytic leukaemia+2

Not yet recruiting

Registered drugNo placebo

Study of EP0042 alone and in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Chronic myelomonocytic leukaemia+1

Not recruiting

InvestigationalNo placebo

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years

Contact Research Centre

Chronic myelomonocytic leukaemia+3

Not recruiting

Registered drugNo placebo

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Allopurinol

Contact Research Centre

Chronic myelomonocytic leukaemia+2

Not recruiting

Registered drugNo placebo

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Registered drugNo placebo

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Chronic myelomonocytic leukaemia

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Chronic myelomonocytic leukaemia+1

Not recruiting

InvestigationalNo placebo

Study of NMS-03592088 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nms-03592088

Contact Research Centre

Find therapies in clinical trials near you

10 trials match your criteria

Chronic myelomonocytic leukaemia+1

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Chronic myelomonocytic leukaemia

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Chronic myelomonocytic leukaemia+3

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

Chronic myelomonocytic leukaemia+2

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Chronic myelomonocytic leukaemia+2

Study of EP0042 alone and in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Chronic myelomonocytic leukaemia+1

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

Chronic myelomonocytic leukaemia+3

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Chronic myelomonocytic leukaemia+2

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Chronic myelomonocytic leukaemia

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Chronic myelomonocytic leukaemia+1

Study of NMS-03592088 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.